Japanese recommendations for RotaTeq, and Iressa in EGFR mutation patients
This article was originally published in Scrip
Executive Summary
In another step towards closing the country's 'vaccine lag', Japan has recommended the approval of MSD's (Merck & Co) oral rotavirus vaccine RotaTeq, paving the way for it to become the second such product to be granted full local marketing authorisation.